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Pertussis is a severe respiratory disease caused by infection with the bacterial pathogen Bordetella pertussis. The disease affects
individuals of all ages but is particularly severe and sometimes fatal in unvaccinated young infants. Other Bordetella species
cause diseases in humans, animals, and birds. Scientific, clinical, public health, vaccine company, and regulatory agency experts
on these pathogens and diseases gathered in Buenos Aires, Argentina from 5 to 8 April 2016 for the 11th International Bordetella
Symposium to discuss recent advances in our understanding of the biology of these organisms, the diseases they cause, and the
development of new vaccines and other strategies to prevent these diseases. Highlights of the meeting included pertussis epide-
miology in developing nations, genomic analysis of Bordetella biology and evolution, regulation of virulence factor expression,
newmodel systems to study Bordetella biology and disease, effects of different vaccines on immune responses, maternal immu-
nization as a strategy to prevent newborn disease, and novel vaccine development for pertussis. In addition, the group approved
the formation of an International Bordetella Society to promote research and information exchange on bordetellae and to orga-
nize future meetings. A new Bordetella.org website will also be developed to facilitate these goals.
Bordetella pertussis infects the human respiratory tract andcauses the disease pertussis, or whooping cough, which is
characterized by severe and prolonged bouts of coughing. The
disease affects individuals of all ages but is particularly severe in
young infants, especially of prevaccination age, in which the
disease can be fatal (1). Pertussis is reemerging in epidemics in
several countries, including the United States, where the num-
ber of reported cases in 2012 was the highest since the 1950s.
Previously used whole-cell pertussis (wP) vaccines have been
replaced in much of the developed world by less reactogenic
acellular pertussis (aP) vaccines, but the use of these new vac-
cines may have contributed to the changing epidemiology of
disease and evolution of the organism (2). There is general
consensus in the field that novel vaccines or novel immuniza-
tion strategies are needed to combat the increasing epidemics
and to protect newborns from fatal disease. Bordetella paraper-
tussis and Bordetella holmesii are related pathogens that can also
cause pertussislike disease in humans, but the incidence of dis-
ease caused by these pathogens is lower than that caused by B.
pertussis and these organisms are still relatively poorly under-
stood. Bordetella bronchiseptica is another related and more
complex pathogen that causes respiratory disease in a number
of different animal species, as well as infections in immuno-
compromised humans. Much is still unclear about the basic
biology of these organisms, the pathogenesis of the diseases
they cause, and themost effective strategies to treat and prevent
these infections and diseases. Many members of the Bordetella
community, including experts in scientific, clinical, public
health, vaccine manufacturing, and regulatory fields, met in
Buenos Aires, Argentina in April 2016 to discuss recent ad-
vances in these areas. As well as oral presentations, there were
lively poster sessions each day with over a hundred poster pre-
sentations on a wide variety of topics. The following sections
describe the highlights of the oral presentations in the various
sessions of the symposium.
EPIDEMIOLOGY AND SURVEILLANCE
Session 1 focused on epidemiology, surveillance, and vaccine ef-
fectiveness. It was organized to give an overview of surveillance
methods for pertussis, two examples of pertussis epidemiology,
and factors relating to fatal pertussis in young infants. The vaccine
section included overviews of methods for estimating vaccine ef-
fectiveness and results frommaternal immunization in theUnited
Kingdom, and a more rational use of acellular vaccines in the
United States was considered. Nicole Guiso (Institut Pasteur,
Paris, France) explained that although pertussis vaccines have
been widely used for more than 50 years and have led to a signif-
icant reduction ofmorbidity andmortality, surveillance of pertus-
sis is still required worldwide. Surveillance of pertussis can be
done by statutory notification, by hospital-based surveillance, by
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sentinel-based surveillance, or by seroepidemiology. Irrespective
of the method of surveillance, a specific biological diagnosis is
needed, as other infections can mimic pertussis symptoms. Fur-
thermore, it is also important to monitor the circulating bacterial
isolates. Dr. Guiso presented examples of surveillance methods
from different countries that may be used as a blueprint when
setting up a surveillance program or analyzing an outbreak. Sur-
veillance thus can define the burden of disease, facilitate the adap-
tation of vaccine strategies according to the type of pertussis vac-
cine used, and follow the evolution of the bacteria, allowing timely
detection of escape mutants. Rudzani Muloiwa (Cape Town,
South Africa) showed that 20 to 40million cases of pertussis occur
worldwide, resulting in 300,000 deaths, of which 90% are in low-
and middle-income countries. From these countries, however,
surveillance data are largely missing, and without these data, it is
difficult if not impossible to review and amend pertussis control
policies. He showed data from a systematic review of pertussis
trends in these countries over a 40-year period since the inception
of the Expanded Program on Immunization (EPI) in 1974 (3). He
also discussed factors that have an impact on surveillance and
burden reduction, as well as the role of diagnostics and choice of
vaccine schedule, and he pointed to variables that are specific to
the epidemiology in low- and middle-income countries. Maria
Lucia Tondella (CDC, Atlanta, GA, USA) reported on the im-
proved understanding of the burden of pertussis in Latin America
from strengthening and standardizing laboratory-based surveil-
lance in these countries. To achieve this, an in-country surveil-
lance system with extensive laboratory capacities has been estab-
lished. She presented the primary achievements of this study but
also highlighted challenges to the implementation and sustain-
ability of surveillance in Latin America. James Cherry (UCLA, Los
Angeles, CA, USA) showed data about four studies on factors
relating to infant deaths from pertussis. High and rapidly rising
white blood cell counts, high and rapidly rising pulse and respira-
tory rates, and pneumonia with early onset were risk factors for
infant death. The fatal cases also had lower birth weight, younger
gestational age, and younger age at the onset of symptoms. Fatal
cases mostly had shock/hypotension, and some had organ failure.
Fatal cases were also less likely to have received macrolides but
more likely to have received corticosteroids and/or nitric oxide.
The role of exchange transfusion to prevent infants dying from
pertussis is currently being evaluated.
In the vaccine section of this session, Natasha Crowcroft (Pub-
lic Health Ontario, Toronto, ON, Canada) discussed the issue of
how to measure pertussis vaccine effectiveness. Study designs in-
clude case-control studies using a variety of controls, cohort- and
household-based approaches, and the screening method. Each
method and data source has different associated strengths, degrees
of feasibility, weaknesses, and biases. Studies are often conducted
in specific contexts, such as during epidemic cycle peaks or out-
breaks in specific settings, which may bias estimates. A partner-
ship among clinicians, public health practitioners, mathematical
modelers, microbiologists, and immunologists would help in de-
termining methods and definitions and in designing future stud-
ies to improve the understanding of how well and how long per-
tussis vaccines protect in the field. Gayatri Amirthalingam (Public
Health England, London, United Kingdom) presented the latest
evaluation of the maternal pertussis immunization program in
England, which was introduced in response to a national out-
break. This programcontinues to provide high levels of protection
(90%) for infants whose mothers received pertussis vaccine at
least 1 week prior to delivery, and the levels of effectiveness of the
two vaccine products (3-component and 5-component acellular
vaccines) used in the national program are similarly high. Evalu-
ation of the impact of blunting of the infant’s immune response is
ongoing. In 2016, updated advice on the timing of maternal vac-
cination has been published to recommend offering women per-
tussis vaccine from 16 weeks of gestation onwards. Nicola Klein
(Kaiser Permanente Vaccine Study Center, Oakland, CA, USA)
used data from recent outbreaks of pertussis in California to ad-
vocate for a more effective use of acellular pertussis (aP) vaccines.
She showed that the number of pertussis cases was higher in ado-
lescents who received primary immunization with aP vaccines in
infancy than in those who were immunized with whole-cell per-
tussis (wP) vaccines. More than 90% coverage with aP vaccines
(tetanus-diphtheria-acellular pertussis [Tdap], which has reduced
antigen content, versus diphtheria-tetanus-acellular pertussis
[DTaP], used in infants) in adolescents did not prevent outbreaks,
and protection waned relatively rapidly. Thus, aP vaccines with
reduced antigen content provide only modest benefit for 2 to 3
years after vaccination, and universal adolescent vaccination is
unlikely to have a major impact on pertussis outbreaks or the
burden of disease. Given these findings, it should be considered
whether a new strategy for the use of aP vaccines can be deployed
to more effectively contain pertussis.
BIOLOGY, GENOMICS, AND EVOLUTION
The session on biology, genomics, and evolution encompassed
functional genomics, evolutionary genomics, and vaccine antigen
deficiency of B. pertussis isolates that probably resulted from se-
lection pressure from vaccine-induced immunity (4–14). New
transcriptomics data expanded our understanding of gene regula-
tion and its complexity in Bordetella biology. Michael Weigand
(CDC, Atlanta, GA, USA) presented the CDC’s massive effort of
sequencing over 260 isolates to produce fully closed genomes us-
ing PacBio and Illumina sequencing and optical mapping. The
advantage of fully completed genomes over draft genomes is that
genome structural changes can be detected and used for phyloge-
netic inference. The data showed that the B. pertussis genome is
structurally fluid, with 62 unique genome architectures identified
among the 260 isolates. Interestingly, certain structural types are
predominant and correlate with pulsed-field gel electrophoresis
(PFGE) patterns, confirming that PFGE predominantly detects
genome structural changes, as expected. Although considerable
structural diversity was seen, some structural changes are fixed in
certain lineages, which may shed light on adaptation.
Andrew Preston (University of Bath) presented new work on
functional genomic analysis of B. pertussis metabolism, which
gave good insight into the biology of infection. B. pertussis uses
amino acids, particularly glutamate, as carbon sources. Using
transposon-directed insertion sequencing (TraDIS) and tran-
scriptome sequencing (RNA-seq) analysis, his group identified
genes essential for growth and genes that are differentially ex-
pressed in Bvg (virulent) and Bvg (avirulent) phases. A flux
balance analysis-based metabolic model was presented. These ap-
proaches identified differences in the levels of activity of the tri-
carboxylic acid (TCA) cycle between Bvg phases that point to a
mechanistic basis for the difference in growth between Bvg and
Bvg phase B. pertussis. Marjolein van Gent (RIVM, the Nether-
lands) presented studies from her group on themolecular charac-
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teristics and epidemiology of B. pertussis populations in the Neth-
erlands, particularly the emergence of strains not expressing the
vaccine antigens pertactin (Prn) and filamentous hemagglutinin
(Fha). They used a multiplex bead-based assay to detect the ex-
pression of the vaccine antigens Prn, Fha, and pertussis toxin
(Ptx). The Netherlands introduced an acellular vaccine in 2005,
and the Prn-deficient isolates seem to be on the rise, from 4% in
2004 to 16% in 2015. Analysis of whole-genome data showed that
B. pertussis can use differentmechanisms to inactivate Prn expres-
sion, and a phylogenetic tree showed that the Prn-deficient iso-
lates were found in different clusters, which suggests positive se-
lection. Her group also identified Fha-negative isolates that result
from phase variation due to a homopolymeric G tract in the cod-
ing region of fhaB that changes from 10 Gs to either 9 or 11 Gs to
turn off expression. Although the frequency of Fha-negative iso-
lates was low, this demonstrated that B. pertussis can potentially
escape Fha-targeted immunity. Valerie Bouchez (Institut Pasteur,
Paris, France) presented a thorough review on vaccine antigen-
deficient B. pertussis and B. parapertussis isolates. B. pertussis iso-
lates deficient for the production of the three key vaccine antigens,
Ptx, Prn, and Fha, have been reported in different areas of the
world (Fig. 1 shows data for Prn-deficient isolates). Ptx- and Fha-
deficient isolates existed well before the introduction of aP vac-
cines, but their incidence has always been very low. In contrast, the
prevalence of Prn-deficient isolates has increased in several areas
of the world that use aP vaccines in recent years, reaching very
high levels in some states of the United States and in Australia in
particular. A review of functional consequences of vaccine antigen
deficiency was also presented. If Prn-deficient B. pertussis isolates
are not more virulent, as evidenced in humans or using in vitro
models (15), they present better fitness than Prn-producing iso-
lates. In addition, Prn-deficient B. parapertussis isolates have been
reported: in France, they have replaced Prn-producing isolates
since 2007. The talk emphasized the need for very close surveil-
lance of vaccine antigen deficiency all around the world, not only
in countries where aP vaccine is used.
Two short talks were both on gene regulation in B. pertussis,
with fascinating insights elucidated through transcriptomic anal-
ysis using RNA-seq. KyungMoon (NIDDK, Bethesda, MD, USA)
presented new findings on Bvg-dependent regulation. Using
RNA-seq, her group showed that about 500 genes had a twofold or
greater difference in gene expression under Bvg regulation, and
over 300 were newly identified genes. Thus, more than 10% of the
genes in the B. pertussis genome may be regulated by the Bvg
system. Newly identified genes included other regulatory genes/
systems, such as kdpE and vrgX, and metabolic genes, including
those for glycolate oxidase (glcFED) and malate synthase (glcB).
Loic Coutte (INSERM, Lille, France) presented newwork on a less
well known two-component regulator, RisA, which adds a new
layer of complexity to the regulation ofB. pertussis gene expression
(Fig. 2). The RisAS system was first identified in B. bronchiseptica,
but in B. pertussis, risS is a pseudogene that encodes a truncated
RisS sensor. His group identified RisK (EnvZ) as the cognate ki-
nase of RisA, and most RisA-regulated genes are RisK dependent.
The genes regulated by RisA and Bvg overlap, and themodulation
of some genes by the Bvg system is dependent on RisA.
VIRULENCE FACTORS AND PATHOGENESIS
Maria Rodriguez (University of La Plata, La Plata, Argentina) de-
scribed findings on intracellular B. pertussis. The bacteria survive
the innate interaction with human macrophages and replicate in
this niche after 48 h, persisting in a compartment with character-
istics of early endosomes, where they have access to recycling ves-
icles. Shotgun proteomic analyses of intracellular bacteria re-
vealed increased production of stress proteins and iron uptake
systems and large changes in the abundance of proteins involved
1-10%
11-40%
>70%
Unknown
Prevalence of pertactin
deficient B. pertussis
FIG 1 World map showing prevalence of Prn-deficient B. pertussis strains in countries where assessments have been made (colored according to the key). The
map was created using mapchart.net (http://mapchart.net/).
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in metabolism, transcription regulation and virulence. The data
suggest that Ptx and adenylate cyclase toxin (Act) contribute to
intracellular survival by manipulating the host cell inflammatory
and microbicidal responses. Intracellular survival of B. pertussis
potentially represents a strategy to increase persistence within
hosts.
Several talks unveiled some of the complexity of gene regula-
tion inB. pertussis. Scott Stibitz (FDA,USA) presented data focus-
ing on the regulation of BvgAS-repressed genes, collectively called
vrgs (virulence-repressed genes) (Fig. 2). Perplexingly, several
studies have identified fim3, encoding FIM3 serotype fimbriae,
which are produced only in the Bvg phase, as a vrg. They identi-
fied a strong Bvg-repressed promoter (BRP) upstream from
Pfim3. Although the BRP is highly expressed in the Bvg– phase, the
assembly of FIM3 fimbriae is only possible in the Bvg phase
when fimbrial biogenesis proteins are produced. Thus, while the
biological relevance of the BRP is unknown, it serves as a useful
reporter for studying the control of vrg expression. Stibitz found
that transcription from BRP under modulating conditions re-
quires the response regulator RisA in a phosphorylated form and
alternative sigma factors. RisA is phosphorylated by an unlinked
sensor kinase, RisK (Fig. 2). Although risK can be mutated, the
response regulator encoded adjacent to RisK (RisR) appears to be
essential. Adding to the complexity of the regulatory network, risR
can be mutated if the bvgS gene contains a mutation that renders
BvgS constitutively active. Further insight into the complexity of
virulence gene regulation inBordetellawas provided by Steve Julio
(Westmont College, Santa Barbara, CA, USA), who identified an-
other two-component regulatory system, PlrSR. He showed that
the bacterial response to CO2 in vitro, which includes increased
production of Act and Fha and higher adherence to host cells,
requires PlrSR. A plrS knockout mutant is defective for coloniza-
tion ofmouse lungs but not of the nose. Using a reporter systemof
promoter expression in vivo, he showed that plrS mutants (but
not wild-type bacteria) switched to the Bvg– phase in the lungs,
while all bacteria remained Bvg in the nose. By combining the
plrS deletion mutation with a constitutive BvgS variant, he
showed that lack of expression of BvgAS-dependent virulence fac-
tors was not the (only) reason that plrS mutants were cleared
from the lower respiratory tract, demonstrating that PlrSR has
both Bvg-dependent and Bvg-independent functions. PlrS may
sense a drop in oxygen level to trigger an appropriate response,
and BvgS may in turn detect a metabolite whose level depends on
the activity of the PlrSR regulon. Umesh Ahuja (UCLA, USA)
described a regulatory node responsible for the differential regu-
lation of type III secretion among Bordetella species. In B. bron-
chiseptica, a type III secretion system (T3SS) causes cytotoxicity
and contributes to persistence in vivo. B. pertussis strains do not
display T3SS-dependent phenotypes, although their T3SS-encod-
ing genes are intact. Transcription of T3SS-encoding genes de-
pends on the extracytoplasmic function (ECF) sigma factor BtrS,
whose gene is Bvg regulated. The secreted BtrA protein antago-
FIG 2 Model showing Bvg regulation of gene expression in B. pertussis and its relationship to the RisK/RisA regulatory system (Copyright Scott Stibitz andQing
Chen). (A) In the Bvg phase, BvgA is phosphorylated by BvgS and activates the transcription of virulence factor genes (vags) and also of the bvgR gene. BvgR
reduces the level of c-di-GMP in the cell, repressing the activity of the RisA transcriptional activator (which is constitutively phosphorylated by RisK in the
presence of truncated RisS). (B) In the Bvg phase, BvgA is not phosphorylated and so no BvgR is produced. High levels of c-di-GMP activate phosphorylated
RisA, which then activates transcription of the vir-repressed genes (vrgs).
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nizes BtrS and positively regulates many genes, including some
virulence factors. Deletion of btrA in B. pertussis derepresses T3SS
genes, leading to the expression of T3SS phenotypes. Rudy An-
toine (Institut Pasteur of Lille, France) presented a structure/func-
tion study of BvgS. A combination of in silico analyses, mutagen-
esis, and cysteine-scanning experiments revealed that a predicted
2-helix coiled-coil between the cytoplasmic PAS domain and the
dimerization and histidine phosphoryl transfer (DHp) domain of
the kinase mechanically determines BvgS activity. In the kinase
mode, the coiled-coil is in a state of great rotational dynamics, and
it shifts to a more rigid conformation upon negative modulation.
Notably, a similar mode of control appears to occur in sensor
kinases homologous to BvgS but devoid of a PAS domain. This
study corroborates the importance of protein dynamics for the
regulation of BvgS activity, as already revealed in a study on its
periplasmic Venus flytrap domains (16).
Sandra Armstrong (University of Minnesota, USA) described
nutrient acquisition in the host. Bordetellae can use heme as an
iron source, and they also chelate iron using alcaligin and xeno-
siderophores. The expression of each system is repressed by iron
and activated by the cognate source, enabling the bacteria to adapt
to changes in their environment. Niacin is also required for Bor-
detella growth, and genes for its utilization are upregulated under
modulating conditions. Intriguingly, B. bronchiseptica can grow
on nicotinic acid and sulfate ions, two molecules known to mod-
ulate BvgS activity, as sole carbon and sulfur sources. Finally,
Nicholas Carbonetti (University of Maryland, Baltimore, MD,
USA) described the upregulation of pendrin in the lungs of B.
pertussis-infected mice and baboons. An epithelial HCO3
/Cl
exchanger, pendrin is involved in asthma pathology in humans
(17).B. pertussis-infected pendrin knockoutmice showed reduced
inflammatory pathology but higher bacterial loads in the lungs.
Treatment with a pendrin inhibitor already in clinical use (acet-
azolamide) decreases lung inflammatory pathology in infected
mice. It also reduces cough in human volunteers (18), suggesting
that it may be used as a novel therapy for pertussis disease.
INVERTEBRATE AND VERTEBRATE MODELS
Investigators from the United States and Argentina presented
their work on invertebrate and vertebrate models (Fig. 3), cover-
ing several areas related to Bordetella infection, pathogenesis,
transmission, and disease as examined in amoeba,mouse, pig, and
baboon models. Eric Harvill (University of Georgia, Athens, GA,
USA) demonstrated that Dictyostelium discoideum could theoret-
ically serve as an environmental reservoir for B. bronchiseptica.D.
discoideum, a unicellular amoebal protozoan, feeds on bacteria by
utilizing phagosomal and endolysosomal mechanisms similar to
those observed in mammalian phagocytes. Harvill presented data
showing that, by facilitating a symbiotic relationship between the
amoeba and the bacteria, the Bvg phase allows bacterial growth
in the amoeba.
Karen Scanlon (University ofMaryland, Baltimore,MD,USA)
described a neonatal mouse infection model for B. pertussis. She
compared B. pertussis pathogenesis and the role of Ptx in this
model and in the well-established adult mouse model. Unlike in-
fection of adult mice, neonatal infection resulted in dose-depen-
dentmortality, whichwas dependent on the expression of Ptx but,
surprisingly, had reduced Ptx-dependent lung inflammatory pa-
thology. Infected neonates displayed disseminated infection and
had Ptx-associated reduction in integrin surface expression on
lymphocytes, white pulp depletion in the spleen, liver pathology,
and disruption of the blood-brain barrier. Together, these data
suggest that impaired immune responses in neonates permit bac-
terial dissemination, systemic Ptx intoxication, and ultimately,
death. The neonatal mouse model represents a powerful tool to
examine the causes of B. pertussis pathogenesis in human infants
and to develop and test future therapeutics.
Rajendar Deora (Wake Forest School of Medicine, Winston
Salem, NC, USA) presented his research on the development of
mouse models of respiratory tract biofilms of Bordetella. Biofilms
are largely defined as multicellular surface-adherent microbial
communities which are encased in a self-produced or host-de-
rived matrix. He presented data that showed the development of
sessile bacterial communities on the nasal and tracheal epithelium
up to 19 days after bacterial inoculation. These respiratory tract
biofilms are encased in a matrix composed of the Bps polysaccha-
ride and are disrupted upon ex vivo treatment of respiratory tract
tissues with DNase I. He concluded that this mouse model of
respiratory tract biofilm corresponds well with experimental ob-
servations on abiotic surface biofilms and represents an appropri-
ate animal model for studying bacterial biofilm infections (19).
Continuing the story on Bordetella biofilms, Natalia Cattelan
(University of La Plata, La Plata, Argentina) presented her re-
search on biofilm formation by recently isolated strains of B. per-
tussis from Argentina and the United States. She demonstrated
that a large number of these isolates displayed a hyperbiofilm phe-
notype. Enhanced biofilm formation inmany of these strains cor-
related with enhanced bacterial autoaggregation and Fha produc-
tion (a protein previously shown to promote biofilm formation in
B. pertussis). Cattelan demonstrated further that some of these
strains demonstrated hyperadherence to lung epithelial cells and
colonized at higher numbers in the mouse nose, trachea, and
lungs. Cattelan proposed that enhanced biofilm formation by re-
cent clinical isolates may explain the continued circulation of B.
pertussis and the resurgence of pertussis infection and disease.
TracyNicholson (USDA, Ames, IA, USA) presented data high-
lighting the contribution of specific virulence factors to B. bron-
chiseptica disease and transmission in swine.Her group found that
the T3SS was required for maximal persistence and airway disease
but not for transmission by either a direct or indirect route, dem-
onstrating that transmission can occur in spite of attenuated dis-
FIG 3 Animal models of Bordetella infection and disease. Mouse, pig, and
baboon models are shown, along with the categories of studies that can be
performed in each of these models.
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ease. Focusing on the role of phenotypic modulation, they were
unable to recover a Bvg phase-locked mutant from any respira-
tory tract site at any time point examined. A Bvg-intermediate
(Bvgi) phase-locked mutant was reduced in respiratory tract col-
onization and caused limited disease in pigs. In contrast, the col-
onization, disease, and transmission caused by a Bvg phase-
locked mutant were indistinguishable from those of the wild-type
strain. These results indicate that the Bvg phase is sufficient for
respiratory infection and transmission of B. bronchiseptica in
swine and that swine serve as an exceptional natural model for
exploring disease and transmission dynamics of bacterial respira-
tory pathogens. Tod Merkel (FDA, Silver Spring, MD, USA) pre-
sented his group’s studies describing the pathogenesis of B. per-
tussis in the baboon model. The histopathology observed in the
trachea and lungs of infant baboons that succumbed toB. pertussis
infection closely matched the histopathology observed in human
infant fatal pertussis cases (1). They observed a pulmonary infec-
tion dominated by necrotizing bronchiolitis, intra-alveolar hem-
orrhage, and fibrinous edema. All samples had marked leukocy-
tosis and showed luminal aggregates of abundant leukocytes in the
small pulmonary blood vessels. They also presented the results of
a comprehensive histopathology study that examined disease pro-
gression in typical, nonfatal cases of pertussis, data that are not
available fromhumanpertussis infections. They observed increas-
ingly severe inflammatory disease in the conducting airways and
lungs with massive infiltration of neutrophils early, replaced by
macrophages later in infection. The lung pathology included in-
tra-alveolar hemorrhage, along with edema and fibrin deposits, as
well as bronchopneumonia typified by acute necrotizing bronchi-
olitis. Large areas of collagen deposition in the lungs were ob-
served late in infection. This extensive scarring may explain, at
least in part, the long-term reduction in lung capacity observed in
children following pertussis infection (20).
IMMUNE RESPONSES TO INFECTION AND IMMUNIZATION
Kingston Mills (Trinity College, Dublin, Ireland) discussed in-
vestigations into mechanisms of immunity induced by wP and
aP vaccines in mouse models. He found that wP but not aP
vaccine induces the development of T follicular helper (Tfh)
cells and tissue-resident memory T and B cells in the lungs,
which contribute to protection against B. pertussis infection. He
also found that agonists that stimulate responses through Toll-
like receptor 2 (TLR2) (BP1569 lipoprotein) or STING (cyclic
di-GMP [c-di-GMP]), added as adjuvants to aP vaccines in
both primary and booster vaccinations, promote protective
Th1 immune responses equivalent to those stimulated by wP
vaccination. However, boosting a previous aP vaccination with
this novel adjuvanted aP vaccine was unable to shift the im-
mune response to a Th1 profile. Giorgio Fedele (Istituto Supe-
riore di Sanità, Rome, Italy) talked about T cell phenotype
skewing by human monocyte-derived dendritic cells (MDDC)
exposed to B. pertussis. He found that despite skewing to a Th1/
Th17 profile, interleukin 12 (IL-12) production is low. IL-
12p40 is induced through p38 mitogen-activated protein
(MAP) kinase, but Act blocks IL-12p35 production by inhibit-
ing the interferon regulatory factor 3 (IRF3)/beta interferon
(IFN-) pathway. He also showed that the live attenuated can-
didate vaccine strain BPZE1 induces proinflammatory cyto-
kines similarly to B. pertussis but that it induces lower levels of
immunopathological prostaglandin E2 (PGE2) through cyclo-
oxygenase 2 (COX-2). This strain also induces suppressor T
cells that are FoxP3 negative but express surface ectoenzymes
that convert ATP or NAD to adenosine, which suppresses T cell
activity.
Cécile van Els (RIVM, Bilthoven, the Netherlands) studied the
dynamics of human B and T cell mechanisms against B. pertussis
following clinical symptomatic infection in search of biomark-
ers of natural immunity. In general, specific antibody and B
and T cell responses declined within 9 months, and yet, parallel
mechanisms may wane differently. She also found that the ex-
tent to which specific lymphocyte populations expand after a
pertussis episode depends on the age of the cases studied and
differs for B and T lymphocytes. The expansion of memory B
cells early in the response is more vigorous with increasing age,
while the capacity of long-termmemory T cells to proliferate to
pertussis antigens deteriorates with age. To increase the knowl-
edge of the antigenic breadth of postinfection immune mech-
anisms, novel antigens other than aP vaccine antigens also need
to be investigated. Anne-Marie Buisman (RIVM, Bilthoven,
the Netherlands) talked about differences identified inmemory
immune responses to B. pertussis in school children primed in
infancy with aP or wP vaccines. In a series of clinical studies,
she followed antibody, memory B cell, and T cell responses to
aP vaccine antigens in these children around a set of subse-
quent aP booster immunizations. The levels of antibody and B
cell responses remained higher in aP vaccine-primed children
than in their wP vaccine-primed counterparts before and up to
5 years after a preschool aP booster vaccination at 4 years of
age. However, after an additional aP vaccination at 9 years of
age, aP vaccine-primed children responded more weakly. At
the T cell level, she found significantly lower IFN-/IL-13
(Th1/Th2) ratios in the PBMC culture supernatants of aP vac-
cine-primed children than in those of wP vaccine-primed chil-
dren around the extra aP vaccination at 9 years of age, high-
lighting the inferiority of aP vaccine priming for the
maintenance of subsequent protective responses. Tod Merkel
(FDA, USA) described immune responses to infection and vac-
cination in the baboonmodel. Infection inducesmultiple cytokines
and chemokines, including IL-17, detected in nasopharyngeal
washes, correlating with the airway neutrophil influx seen in his-
topathology samples. He summarized published data on re-
sponses to wP and aP vaccines and showed that aP vaccination
does not induce IL-17 recall responses (in contrast to wP vaccine)
and appears to delay clearance of the infection. Maternal immu-
nization with aP vaccine protects newborns from pertussis, and
anti-Ptx antibody responses are sufficient for this effect. He also
described a three-pronged approach to new vaccine antigen dis-
covery, using transposon mutant pool sequencing (Tn-seq) for
gene discovery, RNA-seq for gene induction, and immunopro-
teomics for antibody responses.
In short talks, Joshua Eby (University of Virginia, Charlot-
tesville, VA, USA) described toxin neutralization assays and
enzyme-linked immunosorbent assays (ELISAs) for anti-Act
antibodies in human and baboon serum. Among serum sam-
ples from humans with pertussis, 72% were ELISA positive for
anti-Act antibodies and 83% were positive for toxin-neutraliz-
ing activity. All sera with anti-Act antibodies detected by ELISA
neutralized toxin activity, and no sera from control patients
were positive for toxin-neutralizing activity. He proposed that
the neutralization assay would be a useful tool for studying the
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antibody responses to Act following infection or immuniza-
tion. Thomas Rice (Imperial College, London, United King-
dom) compared maternal and cord blood cellular (cytokine)
responses to circulating B. pertussis strains and vaccine antigens
in vaccinated versus nonvaccinated mother-infant pairs. Mul-
tiple Th1 and Th2 cytokine responses were higher in vaccinated
pregnancies in both maternal and cord blood samples, though
the responses to Prn-negative and Prn/Fha-negative strains
were higher than the responses to the wild-type strain, suggest-
ing a suppressive effect of these antigens. Similar responses
were seen to the cocktail of vaccine antigens (Ptx/Fha/Prn).
These data provide new insights into the effects of maternal
vaccination beyond simple transfer of antibodies to the infant.
Ciaran Skerry (University of Maryland, Baltimore, MD, USA)
discussed the prophylactic and therapeutic use of sphingosine-
1-phosphate (S1P) receptor agonists to reduce pertussis in-
flammatory pathology in the mouse model. He showed that
S1P receptor 1 on myeloid cells is the relevant target for this
effect. However, Ptx does not inhibit this activity, even though
S1P receptors are G protein-coupled receptors that signal
through Ptx-sensitive Gi proteins, and he speculated on an al-
ternative mechanism involving signaling through -arrestin
and downregulation of type I interferon responses. Andrew
Gorringe (Public Health England, Porton Down, United King-
dom) studied complement interactions with genome-se-
quenced B. pertussis isolates from the United Kingdom. He
found that varying Vag8 expression correlates with C1-esterase
inhibitor deposition, negatively impacting C3b deposition on
the bacterial surface. He also found that recent clinical and
vaccine strains differ widely in their levels of susceptibility to
antibody-independent and antibody-mediated opsonophago-
cytosis (OP). A weaker correlation between C3b deposition
and OP is found for B. pertussis than for Neisseria meningitidis,
suggesting a role for other factors. In a special workshop, func-
tional antibody assays such as OP were discussed in more detail.
VACCINE DESIGN
To explain the resurgence of pertussis disease in the last de-
cades, several causes have been proposed, most of them asso-
ciated with the vaccines currently in use: (i) the decrease of
vaccine effectiveness over time (waning immunity) (21, 22),
(ii) the selection of mutants able to escape immunity induced
by the vaccine (23, 24) and/or (iii) failure of the vaccine to
induce sterilizing immunity to the pathogen and to avoid
transmission (25). With the massive use of wP vaccines since
the 50s, the incidence and mortality associated with pertussis
fell sharply (26). However, reports on safety concerns in the
1970s reduced the confidence in wP vaccines (27, 28). Adverse
reactions to wP vaccines are partly attributed to the presence of
lipopolysaccharides (LPS), the major constituents of the bac-
terial outer membranes. To improve the traditional wP vac-
cines, recently a wP vaccine with reduced amounts of LPS
(Plow) was developed at the Butantan Institute (Brazil). Dur-
ing the Vaccine Design Session, Paulo Lee Ho from this insti-
tute presented results related to the biotechnological process of
Plow production. From 2004 until 2006, the Butantan Institute
has produced several lots at a pilot scale, and since 2007, vari-
ous processes to scale up the production have been evaluated.
He showed that the Plow vaccine produced by industrial cen-
trifugation had an 80% reduction in endotoxin activity com-
pared to that of the traditional wP vaccine. The main protective
immunogens and the integrity of the bacteria were maintained
at the end of that process. The goal of Butantan is to produce
consistent lots under good manufacturing practice conditions
by the centrifugation method in the next few years. Martine
Caroff (LPS-BioSciences, Université de Paris Sud, France) de-
scribed a nontoxic-LPS extraction methodology and mass
spectrometry microanalysis strategies for strain characteriza-
tion. She proposed that these tools could also be useful for
strain characterization and prediction of biological activities.
The adverse events associated with traditional wP vaccines,
which have led to a decrease in acceptance of these vaccines in
several countries (28, 29), prompted the development of aP vac-
cines that contain purified protein antigens of B. pertussis. Al-
though there is no conclusive evidence that wP vaccines cause
infant deaths, brain damage, or severe neurological disorders,
the aP vaccines have gradually replaced wP vaccines in most
industrialized countries, and currently, most European coun-
tries, Japan, Australia, and the United States only use aP vac-
cines in their vaccination schedules. However, several recent
outbreaks were reported in these countries, indicating faster
waning of immunity induced by aP vaccines compared to that
induced by wP vaccines. Accordingly, children primed with wP
vaccines had longer lasting immunity than those primed with
aP vaccines (30, 31). Thus, much interest is now being devoted
to the development of new, alternative options for antipertus-
sis immunization. Data from animal models and human stud-
ies indicate that although antibodies may mediate protection,
cellular Th1 and Th17 responses are responsible for long-last-
ing protection (32). Since current acellular vaccines elicit
mainly a Th2 response, several solutions have been proposed to
improve the Th1/Th17 responses. One possibility is to combine
these vaccines with Th1-driving adjuvants, at least for the
priming doses (33). Scott Halperin (IWK Health Center, Hal-
ifax, Canada) described the development of such a candidate
vaccine, based on a single-immunization platform consisting
of three immune stimulators, namely, host defense peptides,
polyphosphazenes, and poly(I · C)/CpG oligodeoxynucleotides
(ODN). He showed that a single immunization with this vac-
cine candidate induced humoral immune responses (IgG,
IgG1, and IgG2a) in neonatal mice and piglets that were 100- to
1,000-fold stronger than those induced by the currently li-
censed vaccine. In addition, a much earlier onset of immunity,
a clear shift toward a more balanced or Th1 response, and
duration of immunity of more than 2 years were found. Fur-
thermore, the adjuvant platform was highly effective in the
presence of maternal antibodies and against other pathogens,
including respiratory syncytial virus (RSV).
Watanalai Panbangred (Mahidol University, Thailand) de-
scribed results obtainedwith new genetically engineeredB. pertus-
sis strains for recombinant pertussis vaccine production, and
Punnee Pitisuttithum (Mahidol University, Thailand) pre-
sented results of the clinical study performed to assess nonin-
feriority of an aP vaccine containing genetically detoxified Ptx
versus Adacel vaccine in Thai adolescents. She reported that the
new vaccine was tolerated and as safe as the Adacel vaccine but
induced higher levels of neutralizing anti-Ptx antibodies than
Adacel. A different alternative was the acellular vaccine candi-
date presented by Daniela Hozbor (La Plata National Univer-
sity, Argentina). Her team has developed a new vaccine based
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on outer membrane vesicles (OMVs), which have been shown
to be safe and to induce protection in mice. Furthermore, it
elicits an immune response with a mixed Th1, Th2, and Th17
profile and also induces a robust antibody response. Interest-
ingly, this OMV-based vaccine induced antibodies similar to
those induced by commercial wP and aP vaccines, which con-
tribute to protection against B. pertussis infection in mice. This
OMV-based vaccine was shown to protect against different B. per-
tussis strains with different genetic backgrounds, including
those not expressing Prn. The presence of a high number of
immunogens in the vaccine formulation was presented as an
important advantage, since this formulation may avoid the se-
lective pressure conferred by vaccines containing only a single
or a few protective antigens.
Finally, an entirely different approach was taken by Camille
Locht (Inserm, Institut Pasteur de Lille, France). He presented
the recent progress on a live attenuated pertussis vaccine
(BPZE1) to be delivered by the nasal route. This vaccine is
expected to protect not only against pertussis disease but also
against B. pertussis infection and, therefore, against transmis-
sion. Work on baboon models has shown that, in contrast to
wP and aP vaccines, prior infection protects against both dis-
ease and infection (25). Based on this observation, it was felt
that the best way to protect against infection is nasal vaccina-
tion with a vaccine that mimics infection as much as possible
without causing disease. Preclinical data on the live vaccine
BPZE1 were presented, showing that the vaccine induced long-
lasting protection after a single nasal administration and that it
was safe even in severely immunocompromised animals. A
first-in-human clinical trial showed that BPZE1 is safe in hu-
man adults and is able to transiently colonize the human naso-
pharynx and to induce immune responses to all tested antigens
in all colonized subjects. A dose optimization study is now
ongoing, the results of which are expected in approximately 1
year.
SUMMARY
It became clear from the presentations in the Vaccine Design ses-
sion and in a collective roundtable discussion on the future of
pertussis vaccines that after 20 years of relative silence, a newmo-
mentum in pertussis vaccine development has emerged. Several
complementary approaches are being undertaken in various parts
of theworld, both in academia and in industry. Significant hurdles
still remain, including overcoming the adverse immunological
priming by aP vaccines and the uncertainty associated with com-
pletely new vaccine strategies, but it is hoped that at least some of
these vaccine developments will be successful in reaching the pop-
ulations at need and help to provide improved tools ultimately to
control pertussis disease and transmission. Many aspects of the
basic biology, infection, and disease pathogenesis associated with
B. pertussis and other bordetellae are not sufficiently well under-
stood yet, but the knowledge that is progressively being acquired
and shared at these symposiawill without doubt be of great benefit
for optimized vaccination and therapeutic strategies against
whooping cough.
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